Last reviewed · How we verify

Cisplatin, Capecitabine, Telatinib

ACT Biotech, Inc · Phase 2 active Small molecule

Cisplatin, Capecitabine, Telatinib is a Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor Small molecule drug developed by ACT Biotech, Inc. It is currently in Phase 2 development for Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer, Renal cell carcinoma, Head and neck cancer.

Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, and Telatinib is a tyrosine kinase inhibitor that targets the VEGFR and PDGFR pathways.

Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, and Telatinib is a tyrosine kinase inhibitor that targets the VEGFR and PDGFR pathways. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer, Renal cell carcinoma, Head and neck cancer.

At a glance

Generic nameCisplatin, Capecitabine, Telatinib
SponsorACT Biotech, Inc
Drug classPlatinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor
TargetDNA, Thymidylate synthase, VEGFR, PDGFR
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Cisplatin's mechanism of action involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription. Capecitabine's active metabolite, 5-fluorouracil, is a thymidylate synthase inhibitor, which prevents DNA synthesis. Telatinib's inhibition of VEGFR and PDGFR pathways disrupts angiogenesis and cell proliferation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cisplatin, Capecitabine, Telatinib

What is Cisplatin, Capecitabine, Telatinib?

Cisplatin, Capecitabine, Telatinib is a Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor drug developed by ACT Biotech, Inc, indicated for Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer, Renal cell carcinoma, Head and neck cancer.

How does Cisplatin, Capecitabine, Telatinib work?

Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, and Telatinib is a tyrosine kinase inhibitor that targets the VEGFR and PDGFR pathways.

What is Cisplatin, Capecitabine, Telatinib used for?

Cisplatin, Capecitabine, Telatinib is indicated for Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer, Renal cell carcinoma, Head and neck cancer.

Who makes Cisplatin, Capecitabine, Telatinib?

Cisplatin, Capecitabine, Telatinib is developed by ACT Biotech, Inc (see full ACT Biotech, Inc pipeline at /company/act-biotech-inc).

What drug class is Cisplatin, Capecitabine, Telatinib in?

Cisplatin, Capecitabine, Telatinib belongs to the Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor class. See all Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor drugs at /class/platinum-based-chemotherapy-antimetabolite-tyrosine-kinase-inhibitor.

What development phase is Cisplatin, Capecitabine, Telatinib in?

Cisplatin, Capecitabine, Telatinib is in Phase 2.

What are the side effects of Cisplatin, Capecitabine, Telatinib?

Common side effects of Cisplatin, Capecitabine, Telatinib include Nausea and vomiting, Neutropenia, Thrombocytopenia, Diarrhea, Fatigue.

What does Cisplatin, Capecitabine, Telatinib target?

Cisplatin, Capecitabine, Telatinib targets DNA, Thymidylate synthase, VEGFR, PDGFR and is a Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor.

Related